Bank of America reissued an underperform rating for Amphastar Pharmaceuticals on June 29, 2026.
4 reports, 2 independent
Updated Jun 29
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bank of America reissued an underperform rating for Amphastar Pharmaceuticals on June 29, 2026.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Bank of America downgraded Amphastar Pharmaceuticals to Underperform.1 source
Amphastar's underperform rating was reaffirmed and price target lowered, alongside a buy rating from Berenberg Bank.1 source
Keep exploring
The entities involved
-
Amphastar Pharmaceuticals
publicly traded American pharmaceutical company
Nothing else this week.
-
Bank of America
American multinational banking and financial services corporation
Related events
- Bank of America restated an underperform rating for PVH Corp. on August 17, 2026.
- Bank of America issued an Underperform rating for Campbell’s on September 3, 2026.
- Bank of America restated a buy rating on an unnamed company on August 17, 2026.
- Bank of America boosted its price target and gave a buy rating for Guardian Pharmacy Services, Inc. on September 15, 2026. Truist Financial also boosted its target price and gave a buy rating on the same day.
- Bank of America restated a buy rating on shares of Autodesk.